Illegal E-cigarette Sales Crackdown in Indian Market: 6 Arrested

Regulations by 2FIRSTS.ai
Mar.12.2024
Illegal E-cigarette Sales Crackdown in Indian Market: 6 Arrested
Six people arrested in Chennai for illegal sale of e-cigarettes banned by Tamil Nadu government, with 1312 seized. Police continue crackdown.

According to The Times of India, on March 11th, serious violations were reported at the Nellai Palayam market in India. Police have arrested six individuals on suspicion of illegal selling e-cigarettes in a specific area. These e-cigarettes are prohibited from being sold by the Tamil Nadu government, and a total of 1312 were seized at the scene.

 

Law enforcement officers began intensive searches after the regulations were issued. Sandip Rai Rathore, the Commissioner of City Police in Chennai, stated in a public declaration that substantial progress has been made. The police are actively pursuing the matter, conducting covert investigations at e-cigarette sales points, and have already made arrests of suspects.

 

According to information provided by the police, two men were arrested on March 9 for allegedly selling prohibited e-cigarettes secretly in a store. Additionally, four other suspects were also arrested in a subsequent search operation.

 

This operation resulted in the seizure of 1312 e-cigarettes, with 6 suspects currently facing charges. The police are preparing to take appropriate legal action against them.

 

According to the latest information released by the police, there will be continued strict monitoring of this situation. Those who smuggle, hide, or sell any prohibited items, including e-cigarettes banned by the Tamil Nadu government, will face serious consequences.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Singapore to Extend Etomidate Controls and Table New Vape Legislation in 2026
Singapore to Extend Etomidate Controls and Table New Vape Legislation in 2026
Singapore will maintain etomidate’s classification under drug control laws while preparing new legislation targeting e-vaporisers, as authorities reinforce a hardline regulatory stance on vaping.
Feb.05
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
A cross-sectional analysis based on the US NHANES 2021–2023 cycle, including 6,262 participants aged over 12, found that compared with people who neither smoke nor vape, those who smoke and/or use e-cigarettes had a higher prevalence of elevated blood pressure and hypertension. After full adjustment, smoking/vaping was associated with elevated blood pressure (aOR 1.34) and hypertension (aOR 1.46), and with a 1.05 mmHg higher diastolic blood pressure.
Feb.09 by 2FIRSTS.ai
Cambodian's Phnom Penh Military Police continue crackdown after 300,000-device raid
Cambodian's Phnom Penh Military Police continue crackdown after 300,000-device raid
Phnom Penh Military Police said they have continued cracking down on locations selling electronic devices used for smoking chemicals, following a major raid last week that confiscated 300,000 electronic smoking devices.
Jan.20 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11
PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
Philip Morris International said it presented scientific evidence to the U.S. Food and Drug Administration’s Tobacco Products Scientific Advisory Committee to support its ZYN nicotine pouches seeking a modified risk tobacco product designation, which would allow the company to communicate to adult smokers that switching completely to ZYN could reduce the risk of multiple smoking-related diseases.
Jan.26 by 2FIRSTS.ai
U.S. FDA posts TPSAC meeting materials ahead of discussion on ZYN MRTP applications
U.S. FDA posts TPSAC meeting materials ahead of discussion on ZYN MRTP applications
On January 20, 2026, the U.S. Food and Drug Administration (FDA) posted meeting materials ahead of a virtual Tobacco Products Scientific Advisory Committee (TPSAC) meeting scheduled for January 22, 2026, to discuss modified risk tobacco product (MRTP) applications submitted by Swedish Match USA, Inc. for 20 ZYN nicotine pouch products.
Jan.21 by 2FIRSTS.ai